The role of pharmacists in supporting service users to optimise antipsychotic medication.
Antipsychotic medication
Medicines optimisation
Serious mental illness
Shared decision-making
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
04
04
2023
accepted:
22
07
2023
medline:
26
10
2023
pubmed:
14
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
Pharmacists have a contribution to make in improving optimising medication use for people on antipsychotic medication. The rates of prescribing antipsychotics have increased in England with an 18% rise from 2015 to 2020. People on antipsychotic medication are not treated as equal partners in conversations about their medications. This can leave people to make decisions about their antipsychotic medications without input from their prescribers which can have significant consequences for individuals. Involving people in the decision-making process, as experts on their own condition, has the potential to improve treatment outcomes. The evidence suggests that involving pharmacists in supporting people with serious mental illnesses will lead to improved clinical outcomes. Key areas for pharmacist involvement are providing information, education and counselling on antipsychotic medication and the side effects and reducing polypharmacy especially when antipsychotics are prescribed off license.
Identifiants
pubmed: 37704913
doi: 10.1007/s11096-023-01630-9
pii: 10.1007/s11096-023-01630-9
pmc: PMC10600309
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1293-1298Informations de copyright
© 2023. The Author(s).
Références
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. 2014. https://www.nice.org.uk/guidance/cg178 .
Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–71. https://doi.org/10.1016/s0140-6736(12)60239-6 .
doi: 10.1016/s0140-6736(12)60239-6
pubmed: 22560607
Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429–47. https://doi.org/10.1038/sj.mp.4002136 .
doi: 10.1038/sj.mp.4002136
pubmed: 18180760
Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry. 2000;61(4):5–13.
pubmed: 10811237
Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004;10(18):2219–29.
doi: 10.2174/1381612043384088
pubmed: 15281897
Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13(2):153–60. https://doi.org/10.1002/wps.20128 .
doi: 10.1002/wps.20128
pubmed: 24890068
pmcid: 4102288
Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment–pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169–79. https://doi.org/10.1016/j.pharmthera.2009.10.010 .
doi: 10.1016/j.pharmthera.2009.10.010
pubmed: 19931306
Hálfdánarson Ó, Zoëga H, Aagaard L, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017;27(10):1064–76. https://doi.org/10.1016/j.euroneuro.2017.07.001 .
doi: 10.1016/j.euroneuro.2017.07.001
pubmed: 28755801
NHS Business Authority. Medicines Used in Mental Health - England - 2015/16 to 2021/22. 2022. https://www.nhsbsa.nhs.uk/statistical-collections/medicines-used-mental-health-england/medicines-used-mentalhealth-england-201516-202122
Marston L, Nazareth I, Petersen I, et al. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open. 2014;4(12):e006135. https://doi.org/10.1136/bmjopen-2014-006135 .
doi: 10.1136/bmjopen-2014-006135
pubmed: 25524544
pmcid: 4281533
Højlund M, Pottegård A, Johnsen E, et al. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016. Br J Clin Pharmacol. 2019;85(7):1598–606. https://doi.org/10.1111/bcp.13945 .
doi: 10.1111/bcp.13945
pubmed: 30927284
pmcid: 6595354
Maglione M, Maher AR, Hu J et al. Off-label use of atypical antipsychotics: An update. In: Comparitive Effectiveness Reviews, No. 43. Agency for Healthcare Research and Quality (US), Rockville (MD). 2011. https://www.ncbi.nlm.nih.gov/books/NBK66081/ .
Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21(23):3280–97.
doi: 10.2174/1381612821666150619092903
pubmed: 26088115
Radojčić MR, Pierce M, Hope H, et al. Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000–19 primary care data. Lancet Psychiatry. 2023;10(2):119–28. https://doi.org/10.1016/S2215-0366(22)00404-7 .
doi: 10.1016/S2215-0366(22)00404-7
pubmed: 36638816
Sultan RS, Wang S, Crystal S, et al. Antipsychotic treatment among youths with Attention-Deficit/Hyperactivity disorder. JAMA Netw Open. 2019;2(7):e197850–e. https://doi.org/10.1001/jamanetworkopen.2019.7850 .
doi: 10.1001/jamanetworkopen.2019.7850
pubmed: 31348506
pmcid: 6661708
Dyer SM, Harrison SL, Laver K, et al. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2018;30(3):295–309. https://doi.org/10.1017/S1041610217002344 .
doi: 10.1017/S1041610217002344
pubmed: 29143695
Harrison F, Cations M, Jessop T, et al. Prolonged use of antipsychotic medications in long-term aged care in Australia: a snapshot from the HALT project. Int Psychogeriatr. 2020;32(3):335–45. https://doi.org/10.1017/S1041610219002011 .
doi: 10.1017/S1041610219002011
pubmed: 31969207
Birnbaum ML, Saito E, Gerhard T, et al. Pharmacoepidemiology of antipsychotic use in youth with ADHD: Trends and Clinical Implications. Curr Psychiatry Rep. 2013;15(8):382. https://doi.org/10.1007/s11920-013-0382-3 .
doi: 10.1007/s11920-013-0382-3
pubmed: 23881713
pmcid: 4010184
Shiers DE, Rafi I, Cooper SJ, et al. 2014 update (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version) Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis or schizophrenia. 2014 update. Royal College of Psychiatrists, London.
Ali RA, Jalal Z, Paudyal V. Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: a systematic review. BMC Psychiatry. 2020;20(1):581. https://doi.org/10.1186/s12888-020-02990-6 .
doi: 10.1186/s12888-020-02990-6
pubmed: 33276762
pmcid: 7718699
Grünwald LM, Duddy C, Byng R, et al. The role of trust and hope in antipsychotic medication reviews between GPs and service users a realist review. BMC Psychiatry. 2021;21(1):390. https://doi.org/10.1186/s12888-021-03355-3 .
doi: 10.1186/s12888-021-03355-3
pubmed: 34348680
pmcid: 8340528
Nash A, Kingstone T, Farooq S, et al. Switching antipsychotics to support the physical health of people with severe mental illness: a qualitative study of healthcare professionals’ perspectives. BMJ Open. 2021;11(2):e042497. https://doi.org/10.1136/bmjopen-2020-042497 .
doi: 10.1136/bmjopen-2020-042497
pubmed: 33637542
pmcid: 7919576
Morrison P, Stomski N. Experiences of Family Carers for Persons using antipsychotic medication. Aust NZealand J Fam Ther. 2017;38(3):498–513. https://doi.org/10.1002/anzf.1228 .
doi: 10.1002/anzf.1228
Doane MJ, Sajatovic M, Weiden PJ, et al. Antipsychotic treatment experiences of people with Schizophrenia: patient perspectives from an online survey. Patient Prefer Adherence. 2020;14:2043–54. https://doi.org/10.2147/PPA.S270020 .
doi: 10.2147/PPA.S270020
pubmed: 33149559
pmcid: 7604247
Doane MJ, Bessonova L, Friedler HS, et al. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 2022;22(1):114. https://doi.org/10.1186/s12888-022-03758-w .
doi: 10.1186/s12888-022-03758-w
pubmed: 35164737
pmcid: 8842889
Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724–42. https://doi.org/10.1093/schbul/sbj075 .
doi: 10.1093/schbul/sbj075
pubmed: 16707778
pmcid: 2632258
Yaegashi H, Kirino S, Remington G, et al. Adherence to oral antipsychotics measured by electronic adherence monitoring in Schizophrenia: a systematic review and meta-analysis. CNS Drugs. 2020;34(6):579–98. https://doi.org/10.1007/s40263-020-00713-9 .
doi: 10.1007/s40263-020-00713-9
pubmed: 32219681
Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46. quiz 7–8.
doi: 10.4088/JCP.7090su1cj
pubmed: 19686636
Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47–53. https://doi.org/10.4088/jcp.v69n0107 .
doi: 10.4088/jcp.v69n0107
pubmed: 18312037
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23. https://doi.org/10.1056/NEJMoa051688 .
doi: 10.1056/NEJMoa051688
pubmed: 16172203
Begum F, Mutsatsa S, Gul N, et al. Antipsychotic medication side effects knowledge amongst registered mental health nurses in England: a national survey. J Psychiatr Ment Health Nurs. 2020;27(5):521–32.
doi: 10.1111/jpm.12600
pubmed: 31960574
Lambert M, Karow A, Leucht S, et al. Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci. 2010;12(3):393–407. https://doi.org/10.31887/DCNS.2010.12.3/mlambert .
doi: 10.31887/DCNS.2010.12.3/mlambert
pubmed: 20954433
pmcid: 3181974
Lambert M, Schimmelmann BG, Naber D, et al. Early- and delayed antipsychotic response and prediction of Outcome in 528 severely impaired patients with Schizophrenia treated with Amisulpride. Pharmacopsychiatry. 2009;42(06):277–83. https://doi.org/10.1055/s-0029-1234105 .
doi: 10.1055/s-0029-1234105
pubmed: 19924588
Bodén R, Sundström J, Lindström E, et al. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res. 2009;107(2):232–7. https://doi.org/10.1016/j.schres.2008.10.004 .
doi: 10.1016/j.schres.2008.10.004
pubmed: 18957275
Green CA, Polen MR, Janoff SL, et al. Understanding how clinician-patient relationships and relational continuity of care affect recovery from serious mental illness: STARS study results. Psychiatr Rehabil J. 2008;32(1):9–22. https://doi.org/10.2975/32.1.2008.9.22 .
doi: 10.2975/32.1.2008.9.22
pubmed: 18614445
pmcid: 2573468
King SR, Allan M, Lindsey L. “I found hundreds of other people… but I still wasn’t believed” – an exploratory study on lived experiences of antipsychotic withdrawal. Psychosis. 2022. https://doi.org/10.1080/17522439.2022.2141841 .
doi: 10.1080/17522439.2022.2141841
Bjornestad J, Lavik KO, Davidson L, et al. Antipsychotic treatment – a systematic literature review and meta-analysis of qualitative studies. J Mental Health. 2020;29(5):513–23. https://doi.org/10.1080/09638237.2019.1581352 .
doi: 10.1080/09638237.2019.1581352
Kaminskiy E, Zisman-Ilani Y, Morant N, et al. Barriers and enablers to shared decision making in psychiatric medication management: a qualitative investigation of clinician and service users’ views. Front Psychiatry. 2021. https://doi.org/10.3389/fpsyt.2021.678005 .
doi: 10.3389/fpsyt.2021.678005
pubmed: 35368727
pmcid: 8245843
Zisman-Ilani Y, Lysaker P, Hasson-Ohayon I. Shared risk taking: shared decision making in serious mental illness. Psychiatr Serv. 2021;72(4):461–3. https://doi.org/10.1176/appi.ps.202000156 .
doi: 10.1176/appi.ps.202000156
pubmed: 33557595
Fiorillo A, Barlati S, Bellomo A, et al. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Ann Gen Psychiatry. 2020;19(1):43. https://doi.org/10.1186/s12991-020-00293-4 .
doi: 10.1186/s12991-020-00293-4
pubmed: 32774442
pmcid: 7409631
Opler LA, Ramirez PM, Dominguez LM, et al. Rethinking Medication Prescribing Practices in an inner-city hispanic Mental Health Clinic. J Psychiatr Pract. 2004;10:134–40. https://doi.org/10.1097/00131746-200403000-00009 .
doi: 10.1097/00131746-200403000-00009
pubmed: 15330410
Delman J, Clark JA, Eisen SV, et al. Facilitators and barriers to the active participation of clients with Serious Mental Illnesses in Medication decision making: the perceptions of Young Adult clients. J Behav Health Serv Res. 2015;42(2):238–53. https://doi.org/10.1007/s11414-014-9431-x .
doi: 10.1007/s11414-014-9431-x
pubmed: 25056768
Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3–78. https://doi.org/10.1177/0269881119889296 .
doi: 10.1177/0269881119889296
pubmed: 31829775
Horowitz MA, Jauhar S, Natesan S, et al. A method for tapering antipsychotic treatment that May minimize the risk of Relapse. Schizophr Bull. 2021;47(4):1116–29. https://doi.org/10.1093/schbul/sbab017 .
doi: 10.1093/schbul/sbab017
pubmed: 33754644
pmcid: 8266572
Crellin NE, Priebe S, Morant N, et al. An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders. BMC Psychiatry. 2022;22(1):185. https://doi.org/10.1186/s12888-022-03822-5 .
doi: 10.1186/s12888-022-03822-5
pubmed: 35291964
pmcid: 8925064
Yeisen RAH, Bjornestad J, Joa I, et al. Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study. BMC Psychiatry. 2017;17(1):299. https://doi.org/10.1186/s12888-017-1425-9 .
doi: 10.1186/s12888-017-1425-9
pubmed: 28830453
pmcid: 5567881
Ehrlich C, Dannapfel P. Shared decision making: people with severe mental illness experiences of involvement in the care of their physical health. Ment Health Prev. 2017;5:21–6. https://doi.org/10.1016/j.mhp.2016.12.002 .
doi: 10.1016/j.mhp.2016.12.002
Geyt GL, Awenat Y, Tai S, et al. Personal Accounts of discontinuing neuroleptic medication for psychosis. Qual Health Res. 2017;27(4):559–72. https://doi.org/10.1177/1049732316634047 .
doi: 10.1177/1049732316634047
pubmed: 26984364
Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211–9. https://doi.org/10.1177/0091217416636601 .
doi: 10.1177/0091217416636601
pubmed: 27079779
Rungruangsiripan M, Sitthimongkol Y, Maneesriwongul W, et al. Mediating role of illness representation among social support, therapeutic alliance, experience of medication side effects, and medication adherence in persons with schizophrenia. Arch Psychiatr Nurs. 2011;25(4):269–83. https://doi.org/10.1016/j.apnu.2010.09.002 .
doi: 10.1016/j.apnu.2010.09.002
pubmed: 21784285
Matthias MS, Salyers MP, Rollins AL, et al. Decision making in recovery-oriented mental health care. Psychiatr Rehabil J. 2012;35:305–14. https://doi.org/10.2975/35.4.2012.305.314 .
doi: 10.2975/35.4.2012.305.314
pubmed: 22491370
pmcid: 3980461
Weiden PJ. Redefining Medication Adherence in the treatment of Schizophrenia: how current approaches to adherence lead to Misinformation and Threaten Therapeutic Relationships. Psychiatr Clin North Am. 2016;39(2):199–216. https://doi.org/10.1016/j.psc.2016.01.004 .
doi: 10.1016/j.psc.2016.01.004
pubmed: 27216900
Grünwald LM, Thompson J. Re-starting the conversation: improving shared decision making in antipsychotic prescribing. Psychosis. 2021;13(4):373–7. https://doi.org/10.1080/17522439.2021.1903979 .
doi: 10.1080/17522439.2021.1903979
Calcedo-Barba A, Fructuoso A, Martinez-Raga J, et al. A meta-review of literature reviews assessing the capacity of patients with severe mental disorders to make decisions about their healthcare. BMC Psychiatry. 2020;20(1):339. https://doi.org/10.1186/s12888-020-02756-0 .
doi: 10.1186/s12888-020-02756-0
pubmed: 32605645
pmcid: 7324958
Shepherd A, Shorthouse O, Gask L. Consultant psychiatrists’ experiences of and attitudes towards shared decision making in antipsychotic prescribing, a qualitative study. BMC Psychiatry. 2014;14(1):127. https://doi.org/10.1186/1471-244X-14-127 .
doi: 10.1186/1471-244X-14-127
pubmed: 24886121
pmcid: 4009071
Hamann J, Mendel RT, Fink B, et al. Patients’ and psychiatrists’ perceptions of clinical decisions during schizophrenia treatment. J Nerv Ment Dis. 2008;196(4):329–32. https://doi.org/10.1097/NMD.0b013e31816a62a0 .
doi: 10.1097/NMD.0b013e31816a62a0
pubmed: 18414128
Alguera-Lara V, Dowsey MM, Ride J, et al. Shared decision making in mental health: the importance for current clinical practice. Australas Psychiatry. 2017;25(6):578–82.
doi: 10.1177/1039856217734711
pubmed: 29017332
Aref-Adib G, O’Hanlon P, Fullarton K, et al. A qualitative study of online mental health information seeking behaviour by those with psychosis. BMC Psychiatry. 2016;16(1):232. https://doi.org/10.1186/s12888-016-0952-0 .
doi: 10.1186/s12888-016-0952-0
pubmed: 27400874
pmcid: 4940927
Kaar SJ, Gobjila C, Butler E, et al. Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid. BMC Psychiatry. 2019;19(1):309. https://doi.org/10.1186/s12888-019-2304-3 .
doi: 10.1186/s12888-019-2304-3
pubmed: 31646985
pmcid: 6806500
Wheeler A, Crump K, Lee M, et al. Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health. Res Social Adm Pharm. 2012;8(3):179–92. https://doi.org/10.1016/j.sapharm.2011.04.003 .
doi: 10.1016/j.sapharm.2011.04.003
pubmed: 21831724
Younas M, Bradley E, Holmes N, et al. Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness. Int J Clin Pharm. 2016;38(5):1191–9. https://doi.org/10.1007/s11096-016-0352-z .
doi: 10.1007/s11096-016-0352-z
pubmed: 27450504
pmcid: 5031729
Lindsey L, Husband A, Steed L, et al. Helpful advice and hidden expertize: pharmacy users’ experiences of community pharmacy accessibility. J Public Health. 2017;39(3):609–15. https://doi.org/10.1093/pubmed/fdw089 .
doi: 10.1093/pubmed/fdw089
Goldstone LW, DiPaula BA, Caballero J, et al. Improving medication-related outcomes for patients with psychiatric and neurologic disorders: value of psychiatric pharmacists as part of the health care team. Ment Health Clin. 2015;5(1):1–28. https://doi.org/10.9740/mhc.2015.01.001 .
doi: 10.9740/mhc.2015.01.001
Farag M, Hoti K, Hughes J, et al. Impact of a clinical pharmacist on medication safety in mental health hospital-in-the-Home: a retrospective analysis. Int J Clin Pharm. 2022;44(4):947–55. https://doi.org/10.1007/s11096-022-01409-4 .
doi: 10.1007/s11096-022-01409-4
pubmed: 35438472
pmcid: 9016122
Ng R, El-Den S, Stewart V, et al. Pharmacist-led interventions for people living with severe and persistent mental illness: a systematic review. Aust N Z J Psychiatry. 2022;56(9):1080–103. https://doi.org/10.1177/00048674211048410 .
doi: 10.1177/00048674211048410
pubmed: 34560826
Murphy AL, Phelan H, Haslam S, et al. Community pharmacists’ experiences in mental illness and addictions care: a qualitative study. Subst Abuse Treat Prev Policy. 2016;11(1):6. https://doi.org/10.1186/s13011-016-0050-9 .
doi: 10.1186/s13011-016-0050-9
pubmed: 26821700
pmcid: 4730654
Clement S, Schauman O, Graham T, et al. What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychol Med. 2015;45(1):11–27. https://doi.org/10.1017/s0033291714000129 .
doi: 10.1017/s0033291714000129
pubmed: 24569086
Carrotte ER, Hartup ME, Lee-Bates B, et al. I think that everybody should be involved”: what informs experiences of shared decision-making in supporting people living with schizophrenia spectrum disorders? Patient Educ Couns. 2021;104(7):1583–90. https://doi.org/10.1016/j.pec.2020.11.012 .
doi: 10.1016/j.pec.2020.11.012
pubmed: 33229188
Kadra G, Stewart R, Shetty H, et al. Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology. 2018;235(1):281–9. https://doi.org/10.1007/s00213-017-4767-6 .
doi: 10.1007/s00213-017-4767-6
pubmed: 29080904
Tiihonen J, Taipale H, Mehtälä J, et al. Association of Antipsychotic Polypharmacy vs Monotherapy with Psychiatric rehospitalization among adults with Schizophrenia. JAMA Psychiatry. 2019;76(5):499–507. https://doi.org/10.1001/jamapsychiatry.2018.4320 .
doi: 10.1001/jamapsychiatry.2018.4320
pubmed: 30785608
pmcid: 6495354
Rubio-Valera M, Chen TF, Reilly CL. New Roles for pharmacists in Community Mental Health Care: a narrative review. Int J Environ Res Public Health. 2014;11(10):10967–90.
doi: 10.3390/ijerph111010967
pubmed: 25337943
pmcid: 4211017
Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med. 2008;168(10):1090–6. https://doi.org/10.1001/archinte.168.10.1090 .
doi: 10.1001/archinte.168.10.1090
pubmed: 18504337
Morral K, Morral J. The mental health literacy of British community pharmacists. J Mental Health Train Educ Pract. 2017;12:98–110.
doi: 10.1108/JMHTEP-12-2015-0054
O’Reilly CL, Bell JS, Kelly PJ, et al. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Soc Adm Pharm. 2015;11(3):e101–e9. https://doi.org/10.1016/j.sapharm.2013.04.006 .
doi: 10.1016/j.sapharm.2013.04.006
Koodun S, Dudia R, Abifarin B, et al. Racial and ethnic disparities in mental health care. Pharm J. 2021;307:7954.